


What is claimed is:

1. A method of treating migraine, epilepsy, or bipolar disorder in a mammal comprising administering to a mammal a therapeutically effective amount of a compound of formula (I)



(I),

or a pharmaceutically acceptable prodrug thereof, wherein


A is cycloalkyl or bicycloalkyl;

R_A, R_B, and R_C are independently hydrogen or alkyl;

R₁ is OR₂ or NR₃R₄;

R₂ is hydrogen or alkyl;

R₃ and R₄ are independently hydrogen, alkenyl, alkyl, alkynyl, alkoxycarbonylalkyl, aryl, arylalkyl, carboxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycle, heterocyclealkyl, hydroxyalkyl, (NR₅R₆)alkyl, (NR₅R₆)carbonylalkyl, or



R₃ and R₄ taken together with the nitrogen atom to which they are attached form a heterocycle wherein the heterocycle is azepanyl, azetidiny, aziridiny, morpholinyl, piperazinyl, piperidinyl, pyrrolidinyl, or thiomorpholinyl;

R₅ and R₆ are independently hydrogen, alkenyl, alkyl, alkynyl, alkoxycarbonylalkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heterocycle, heterocyclealkyl, or hydroxyalkyl;

R₇ is alkoxy, alkyl, hydroxy, or -NR₅R₆;

R₈ is alkenyl, alkoxyalkyl, alkoxycarbonylalkyl, alkylthioalkyl, alkynyl, aryl, arylalkyl, carboxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycle, heterocyclealkyl, hydroxyalkyl, mercaptoalkyl, (NR₅R₆)alkyl, (NR₅R₆)carbonylalkyl, or -(CH₂)_nNHC(=NH)NH₂; and

n is an integer from 1 to 6;

provided that the compound of formula (I) is other than bicyclo[4.1.0]heptane-7-carboxylic acid.

2. The method according to claim 1 wherein

A is cycloalkyl; and

R₁ is OR₂.

3. The method according to claim 1 wherein

A is cycloalkyl wherein the cycloalkyl is optionally substituted with 1 or 2 alkyl groups ; and

R₁ is OR₂.

4. The method according to claim 3 wherein the compound of formula (I) is

3-methylbicyclo[4.1.0]heptane-7-carboxylic acid;

(exo) (1R,2R,4S,5S)-tricyclo[3.2.1.0^{2,4}]octane-3-carboxylic acid;

2,4-dimethylbicyclo[4.1.0]heptane-7-carboxylic acid;

(trans) 2,4-dimethylbicyclo[4.1.0]heptane-7-carboxylic acid;

(2S,5R)-2-isopropyl-5-methylbicyclo[4.1.0]heptane-7-carboxylic acid;

(endo) bicyclo[6.1.0]nonane-9-carboxylic acid;

(exo) bicyclo[6.1.0]nonane-9-carboxylic acid;

2,7,7-trimethyltricyclo[4.1.1.0^{2,4}]octane-3-carboxylic acid;

1-methylbicyclo[4.1.0]heptane-7-carboxylic acid;

(exo) bicyclo[3.1.0]hexane-6-carboxylic acid;

4,7,7-trimethyltricyclo[4.1.1.0^{2,4}]octane-3-carboxylic acid;

3-tert-butylbicyclo[4.1.0]heptane-7-carboxylic acid;

1-methylbicyclo[3.1.0]hexane-6-carboxylic acid; or

1,5-dimethylbicyclo[4.1.0]heptane-7-carboxylic acid.

5. The method according to claim 1 wherein

A is bicycloalkyl; and

R₁ is OR₂.

6. The method according to claim 1 wherein

A is bicycloalkyl wherein the bicycloalkyl is optionally substituted with 1 or 2 alkyl groups; and

R₁ is OR₂.

7. The method according to claim 6 wherein the compound of formula (I) is
 (1S,3S,5S,7R)-3,8,8-trimethyltricyclo[5.1.0.0^{3,5}]octane-4-carboxylic acid;
 (1S,3S,4R,7R)-3,8,8-trimethyltricyclo[5.1.0.0^{3,5}]octane-4-carboxylic acid;
 (exo) (1aR,2R,2aS,5aR,6S,6aS)-decahydro-2,6-methanocyclopropa[f]indene-1-carboxylic acid;
 (1R,5S)-tricyclo[3.3.0.0^{2,4}]oct-2(4)-ene-3-carboxylic acid;
 octahydro-1H-cyclopropa[a]pentalene-1-carboxylic acid; or
 (1R,2R,4R,7R)-4,8,8-trimethyltricyclo[5.1.0.0^{2,4}]octane-3-carboxylic acid.

8. The method according to claim 1 wherein
 A is cycloalkyl; and
 R₁ is NR₃R₄.

9. The method according to claim 1 wherein
 A is cycloalkyl wherein the cycloalkyl is optionally substituted with 1 or 2 alkyl groups ;
 R₁ is NR₃R₄;
 R₃ is hydrogen;
 R₄ is hydrogen or (NR₅R₆)carbonylalkyl; and
 R₅ and R₆ are hydrogen.

10. The method according to claim 9 wherein the compound of formula (I) is
 (exo) (1R,6S)-bicyclo[4.1.0]heptane-7-carboxamide;
 (exo) (1R,6S)-N-(2-amino-2-oxoethyl)bicyclo[4.1.0]heptane-7-carboxamide;
 3-methylbicyclo[4.1.0]heptane-7-carboxamide;
 N-(2-amino-2-oxoethyl)-3-methylbicyclo[4.1.0]heptane-7-carboxamide;
 (exo) (1R,2R,4S,5S)-tricyclo[3.2.1.0^{2,4}]octane-3-carboxamide;
 (exo) (1R,2R,4S,5S)-N-(2-amino-2-oxoethyl)tricyclo[3.2.1.0^{2,4}]octane-3-carboxamide;
 2,4-dimethylbicyclo[4.1.0]heptane-7-carboxamide;
 N-(2-amino-2-oxoethyl)-2,4-dimethylbicyclo[4.1.0]heptane-7-carboxamide;
 2,4-dimethylbicyclo[4.1.0]heptane-7-carboxamide;

(1S,2S,4S,6R,7S)-N-(2-amino-2-oxoethyl)-2,4-dimethylbicyclo[4.1.0]heptane-7-carboxamide;

(2S,5R)-2-isopropyl-5-methylbicyclo[4.1.0]heptane-7-carboxamide;

(2S,5R)-N-(2-amino-2-oxoethyl)-2-isopropyl-5-methylbicyclo[4.1.0]heptane-7-carboxamide;

(endo) bicyclo[6.1.0]nonane-9-carboxamide;

(endo) N-(2-amino-2-oxoethyl)bicyclo[6.1.0]nonane-9-carboxamide;

(exo) bicyclo[6.1.0]nonane-9-carboxamide;

(exo) N-(2-amino-2-oxoethyl)bicyclo[6.1.0]nonane-9-carboxamide;

2,7,7-trimethyltricyclo[4.1.1.0^{2,4}]octane-3-carboxamide;

N-(2-amino-2-oxoethyl)-2,7,7-trimethyltricyclo[4.1.1.0^{2,4}]octane-3-carboxamide;
1-methylbicyclo[4.1.0]heptane-7-carboxamide;

N-(2-amino-2-oxoethyl)-1-methylbicyclo[4.1.0]heptane-7-carboxamide;

(exo) bicyclo[5.1.0]octane-8-carboxamide;

(exo) N-(2-amino-2-oxoethyl)bicyclo[5.1.0]octane-8-carboxamide;

bicyclo[3.1.0]hexane-6-carboxamide;

(exo) N-(2-amino-2-oxoethyl)bicyclo[3.1.0]hexane-6-carboxamide;

4,7,7-trimethyltricyclo[4.1.1.0^{2,4}]octane-3-carboxamide;

N-(2-amino-2-oxoethyl)-4,7,7-trimethyltricyclo[4.1.1.0^{2,4}]octane-3-carboxamide;
3-tert-butylbicyclo[4.1.0]heptane-7-carboxamide;

N-(2-amino-2-oxoethyl)-3-tert-butylbicyclo[4.1.0]heptane-7-carboxamide;

1-methylbicyclo[3.1.0]hexane-6-carboxamide;

N-(2-amino-2-oxoethyl)-1-methylbicyclo[3.1.0]hexane-6-carboxamide;

1,5-dimethylbicyclo[4.1.0]heptane-7-carboxamide; or

N-(2-amino-2-oxoethyl)-1,5-dimethylbicyclo[4.1.0]heptane-7-carboxamide.

11. The method according to claim 1 wherein

A is bicycloalkyl; and

R₁ is NR₃R₄.


12. The method according to claim 1 wherein

A is bicycloalkyl wherein the bicycloalkyl is optionally substituted with 1 or 2 alkyl groups;

R₁ is NR₃R₄;
R₃ is hydrogen;
R₄ is hydrogen or (NR₅R₆)carbonylalkyl; and
R₅ and R₆ are hydrogen.

13. The method according to claim 12 wherein the compound of formula (I) is
(1S,3S,4S,7R)-3,8,8-trimethyltricyclo[5.1.0.0^{3,5}]octane-4-carboxamide;
(1S,3S,4S,7R)-N-(2-amino-2-oxoethyl)-3,8,8-trimethyltricyclo[5.1.0.0^{3,5}]octane-4-carboxamide;
(exo) (1aR,2R,2aS,5aR,6S,6aS)-decahydro-2,6-methanocyclopropa[f]indene-1-carboxamide;
(exo) (1aR,2R,2aS,5aR,6S,6aS)-N-(2-amino-2-oxoethyl)decahydro-2,6-methanocyclopropa[f]indene-1-carboxamide;
(1R,5S)-tricyclo[3.3.0.0^{2,4}]oct-2(4)-ene-3-carboxamide;
(1R,5S)-N-(2-amino-2-oxoethyl)tricyclo[3.3.0.0^{2,4}]oct-2(4)-ene-3-carboxamide;
octahydro-1H-cyclopropa[a]pentalene-1-carboxamide;
N-(2-amino-2-oxoethyl)octahydro-1H-cyclopropa[a]pentalene-1-carboxamide;
(1R,2R,4R,7R)-4,8,8-trimethyltricyclo[5.1.0.0^{2,4}]octane-3-carboxamide; or
(1R,2R,4R,7R)-N-(2-amino-2-oxoethyl)-4,8,8-trimethyltricyclo[5.1.0.0^{2,4}]octane-3-carboxamide.
14. A method of treating a psychiatric disorder in a mammal comprising administering to a mammal a therapeutically effective amount of a compound of formula (I).
15. A method of treating pain in a mammal comprising administering to a mammal a therapeutically effective amount of a compound of formula (I).
16. A method of treating a movement disorder in a mammal comprising administering to a mammal a therapeutically effective amount of a compound of formula (I).
17. A method of providing neuroprotection in a mammal comprising administering to a mammal a therapeutically effective amount of a compound of formula (I).

18. A compound of formula (II)




or a pharmaceutically acceptable prodrug thereof, wherein

A is cycloalkyl or bicycloalkyl;

R_A , R_B , and R_C are independently hydrogen or alkyl;

R_3 is hydrogen or alkyl;

R_4 is alkenyl, alkynyl, alkoxy carbonylalkyl, carboxyalkyl, cycloalkyl, cycloalkylalkyl, heterocyclealkyl, hydroxyalkyl, (NR_5R_6) alkyl, (NR_5R_6) carbonylalkyl, or



R_3 and R_4 taken together with the nitrogen atom to which they are attached form a heterocycle wherein the heterocycle is azepanyl, azetidiny, aziridiny, morpholiny, piperaziny, piperidiny, pyrrolidiny, or thiomorpholiny;

R_5 and R_6 are independently hydrogen, alkenyl, alkyl, alkynyl, alkoxy carbonylalkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heterocycle, heterocyclealkyl, or hydroxyalkyl;

R_7 is alkoxy, alkyl, hydroxy, or $-NR_5R_6$;

R_8 is alkenyl, alkoxyalkyl, alkoxy carbonylalkyl, alkylthioalkyl, alkynyl, aryl, arylalkyl, carboxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycle, heterocyclealkyl, hydroxyalkyl, mercaptoalkyl, (NR_5R_6) alkyl, (NR_5R_6) carbonylalkyl, or $-(CH_2)_nNHC(=NH)NH_2$; and

n is an integer from 1 to 6.

19. The compound according to claim 18 wherein A is cycloalkyl.

20. The compound according to claim 18 wherein

A is cycloalkyl wherein the cycloalkyl is optionally substituted with 1 or 2 alkyl groups;

R_3 is hydrogen;

R_4 is (NR_5R_6) carbonylalkyl; and

R₅ and R₆ are hydrogen.

21. The compound according to claim 20 wherein the compound of formula (I) is
(exo) (1R,6S)-N-(2-amino-2-oxoethyl)bicyclo[4.1.0]heptane-7-carboxamide;
N-(2-amino-2-oxoethyl)-3-methylbicyclo[4.1.0]heptane-7-carboxamide;
(exo) (1R,2R,4S,5S)-N-(2-amino-2-oxoethyl)tricyclo[3.2.1.0^{2,4}]octane-3-carboxamide;
N-(2-amino-2-oxoethyl)-2,4-dimethylbicyclo[4.1.0]heptane-7-carboxamide;
(1S,2S,4S,6R,7S)-N-(2-amino-2-oxoethyl)-2,4-dimethylbicyclo[4.1.0]heptane-7-carboxamide;
(2S,5R)-N-(2-amino-2-oxoethyl)-2-isopropyl-5-methylbicyclo[4.1.0]heptane-7-carboxamide;
(endo) N-(2-amino-2-oxoethyl)bicyclo[6.1.0]nonane-9-carboxamide;
(exo) N-(2-amino-2-oxoethyl)bicyclo[6.1.0]nonane-9-carboxamide;
N-(2-amino-2-oxoethyl)-2,7,7-trimethyltricyclo[4.1.1.0^{2,4}]octane-3-carboxamide;
N-(2-amino-2-oxoethyl)-1-methylbicyclo[4.1.0]heptane-7-carboxamide;
(exo) N-(2-amino-2-oxoethyl)bicyclo[5.1.0]octane-8-carboxamide;
(exo) N-(2-amino-2-oxoethyl)bicyclo[3.1.0]hexane-6-carboxamide;
N-(2-amino-2-oxoethyl)-4,7,7-trimethyltricyclo[4.1.1.0^{2,4}]octane-3-carboxamide;
N-(2-amino-2-oxoethyl)-3-tert-butylbicyclo[4.1.0]heptane-7-carboxamide;
N-(2-amino-2-oxoethyl)-1-methylbicyclo[3.1.0]hexane-6-carboxamide; or
N-(2-amino-2-oxoethyl)-1,5-dimethylbicyclo[4.1.0]heptane-7-carboxamide.
22. The compound according to claim 18 wherein A is bicycloalkyl.
23. The compound according to claim 18 wherein
A is bicycloalkyl wherein the bicycloalkyl is optionally substituted with 1 or 2 alkyl groups;
R₃ is hydrogen;
R₄ is (NR₅R₆)carbonylalkyl; and
R₅ and R₆ are hydrogen.
24. The compound according to claim 23 wherein the compound of formula (I) is

(1S,3S,4S,7R)-N-(2-amino-2-oxoethyl)-3,8,8-trimethyltricyclo[5.1.0.0^{3,5}]octane-4-carboxamide;

(exo) (1aR,2R,2aS,5aR,6S,6aS)-N-(2-amino-2-oxoethyl)decahydro-2,6-methanocyclopropa[f]indene-1-carboxamide;

(1R,5S)-N-(2-amino-2-oxoethyl)tricyclo[3.3.0.0^{2,4}]oct-2(4)-ene-3-carboxamide;

N-(2-amino-2-oxoethyl)octahydro-1H-cyclopropa[a]pentalene-1-carboxamide; or

(1R,2R,4R,7R)-N-(2-amino-2-oxoethyl)-4,8,8-trimethyltricyclo[5.1.0.0^{2,4}]octane-3-carboxamide.

25. A method of treating neuropathic and inflammatory pain in a mammal comprising administering to a mammal a therapeutically effective amount of a compound of formula (I).